Concepedia

Author

Steven G. Terra

Pfizer (United States)ORCID

Also Known As

S G Terra, S TERRA, S Terra, S. G. Terra, S. Terra, S.G. Terra, STEVEN G. TERRA, STEVEN TERRA, Steve Terra, Steven G Terra

99

Publications

5.8K

Citations

31

H-Index

55

Concepts

All Affiliations

Pfizer (United States)Merck & Co., Inc., Rahway, NJ, USA (United States)Pfizer (France)University of FloridaPfizer (Germany)
SG

About

Steven G. Terra is an author at Pfizer (United States) specializing in medicine, pharmacotherapy, and pharmacology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

12

12

350

2

Diabetes

3

3

57

3

Public Health

2

2

91

4

Health Sciences

1

1

30

5

Endocrinology

1

1

30

Steven G. Terra

×

49

Publications

4.3K

Citations

27

H-Index

YearCitations

Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes

Christopher P. Cannon, Richard E. Pratley, Samuel Dagogo‐Jack,

New England Journal of Medicine

2020

1.4K

Efficacy of Ertugliflozin on Heart Failure–Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease

Francesco Cosentino, Christopher P. Cannon, David Z.I. Cherney,

Circulation

2020

237

Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV)

Christopher P. Cannon, Darren K. McGuire, Richard E. Pratley,

American Heart Journal

2018

202

Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy ( <scp>VERTIS MET</scp> )

Julio Rosenstock, Juan P. Frías, Dénes Páll,

Diabetes Obesity and Metabolism

2017

184

??1-Adrenergic receptor polymorphisms and left ventricular remodeling changes in response to ??-blocker therapy

Steven G. Terra, Karen Hamilton, Daniel Pauly,

Pharmacogenetics and Genomics

2005

171

Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The <scp>VERTIS FACTORIAL</scp> randomized trial

Richard E. Pratley, Roy Eldor, Annaswamy Raji,

Diabetes Obesity and Metabolism

2017

158

Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: The <scp>VERTIS SITA2</scp> placebo‐controlled randomized study

Samuel Dagogo‐Jack, Jie Liu, Roy Eldor,

Diabetes Obesity and Metabolism

2017

155

Ertugliflozin in Patients with Stage 3 Chronic Kidney Disease and Type 2 Diabetes Mellitus: The VERTIS RENAL Randomized Study

George Grunberger, Sarah Camp, Jeremy Johnson,

Diabetes Therapy

2017

147

Phase III, efficacy and safety study of ertugliflozin monotherapy in people with type 2 diabetes mellitus inadequately controlled with diet and exercise alone

Steven G. Terra, Kristen Focht, Melanie J. Davies,

Diabetes Obesity and Metabolism

2017

141

β-adrenergic Receptor Polymorphisms and Responses during Titration of Metoprolol Controlled Release/extended Release in Heart Failure*

Steven G. Terra, Daniel Pauly, Craig R. Lee,

Clinical Pharmacology & Therapeutics

2005

119

Page 1